Cantor Fitzgerald Comments on Belite Bio FY2026 Earnings

Belite Bio, Inc (NASDAQ:BLTE - Free Report) - Cantor Fitzgerald issued their FY2026 earnings per share estimates for Belite Bio in a report released on Monday, June 9th. Cantor Fitzgerald analyst J. Kim forecasts that the company will post earnings per share of ($2.00) for the year. Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Belite Bio's current full-year earnings is ($1.17) per share.

Belite Bio (NASDAQ:BLTE - Get Free Report) last issued its quarterly earnings data on Monday, March 17th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.02).

A number of other equities analysts also recently issued reports on BLTE. HC Wainwright restated a "buy" rating and set a $100.00 price objective on shares of Belite Bio in a research report on Thursday, May 15th. Benchmark restated a "buy" rating and set a $80.00 price objective on shares of Belite Bio in a research report on Wednesday, March 26th. Finally, Wall Street Zen downgraded Belite Bio from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $96.67.

Belite Bio Stock Performance

Shares of BLTE traded down $2.59 during mid-day trading on Wednesday, reaching $59.55. 21,092 shares of the company were exchanged, compared to its average volume of 47,349. Belite Bio has a 52 week low of $43.70 and a 52 week high of $86.53. The stock has a market capitalization of $1.90 billion, a PE ratio of -53.65 and a beta of -1.44. The business has a 50 day simple moving average of $61.01 and a two-hundred day simple moving average of $61.09.

Institutional Investors Weigh In On Belite Bio

Large investors have recently added to or reduced their stakes in the business. Bank of America Corp DE grew its stake in Belite Bio by 36.4% during the fourth quarter. Bank of America Corp DE now owns 18,342 shares of the company's stock worth $1,157,000 after purchasing an additional 4,891 shares during the period. BNP Paribas Financial Markets acquired a new position in Belite Bio during the fourth quarter worth $155,000. GAMMA Investing LLC raised its holdings in Belite Bio by 9,391.6% during the first quarter. GAMMA Investing LLC now owns 122,441 shares of the company's stock worth $8,108,000 after buying an additional 121,151 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Belite Bio by 130.3% during the fourth quarter. JPMorgan Chase & Co. now owns 14,636 shares of the company's stock worth $924,000 after buying an additional 8,280 shares during the last quarter. Finally, XTX Topco Ltd raised its holdings in Belite Bio by 30.9% during the fourth quarter. XTX Topco Ltd now owns 7,062 shares of the company's stock worth $446,000 after buying an additional 1,668 shares during the last quarter. Institutional investors and hedge funds own 0.53% of the company's stock.

Belite Bio Company Profile

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.